What Boston Scientific's 8-K filings say: 10 filings, latest Sep 23, 2026
Boston Scientific filed its latest 8-K with the SEC on Sep 23, 2026. It discusses governance change, restructuring and succession announcement.
Public (BSX)Medical Equipment Manufacturing10,000+ employeesbostonscientific.comLinkedIn
- Filed
- Sep 23, 2026
- Filings
- 10
- Signals
- 30
8-K · latest 10
What Boston Scientific's 8-K filings say
- SEC EDGAR
8-K
Filed · 3 signals
EVP & Group President of MedSurg and Asia Pacific to retire Jan 1, 2027
The retirement of Arthur C.
$0.8M
Retiring EVP's current annual base salary
- SEC EDGAR
8-K
Filed · 4 signals
A cybersecurity incident on August 25, 2026, caused a network outage affecting operating systems and business applications, which disrupted manufacturing, order processing, and shipping.
The company has determined the operational disruption from a recent cybersecurity incident will have a material impact on its results, making it unlikely to meet its previously issued net sales growth and adjusted EPS guidance.
This signals urgent, unbudgeted spending on cybersecurity services and technology to restore operations and prevent future breaches, as the event is expected to materially impact quarterly and full-year results.
- SEC EDGAR
8-K
Filed · 4 signals
A major cybersecurity attack has crippled key IT systems, causing a global disruption to operations and halting the company's ability to process and ship customer orders.
Boston Scientific hires third-party experts to contain and investigate major cybersecurity incident.
In response to a system-wide cyber attack, the company has engaged external cybersecurity experts for incident response and investigation.
- SEC EDGAR
8-K
Filed · 1 signal
Boston Scientific launches $2B accelerated share repurchase program, signaling strong cash position.
The company entered a $2 billion accelerated share repurchase (ASR) agreement, indicating significant financial health and available capital.
$2B
Accelerated share repurchase agreement price
JPMorgan Chase Bank, National Association
- SEC EDGAR
8-K
Filed · 4 signals
Boston Scientific invests $1.5B in MiRus with a $3B option to acquire its TAVR business.
This multi-billion dollar strategic investment and potential acquisition will necessitate a significant post-merger integration effort for the new company and product line.
$1.5B
Initial cash payment for equity in MiRus LLC, with a $3.0 billion option for a future acquisition.
33.75%
Acquired non-voting common equity interests in MiRus LLC.
MiRus LLC
Boston Scientific backs pivotal US clinical trial for new TAVR System.
The investment supports the STAR randomized control clinical trial, which requires FDA approval.
MiRus LLC
Earlier 8-K filings
Showing 10 of 30 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Boston Scientific with the Signal API
One POST /v1/companies/enrich call with bostonscientific.com returns Boston Scientific 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bostonscientific.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about Boston Scientific 8-K
When did Boston Scientific file its latest 8-K?
What did Boston Scientific disclose in its latest 8-K?
Where can I read Boston Scientific's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .